Clinical Trials
41
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)β’ Click on a phase to view related trials
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
- Conditions
- Coronary Artery Disease (CAD)Peripheral Artery Disease (PAD)
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 277
- Registration Number
- NCT06052319
- Locations
- πΊπΈ
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
πΊπΈHCA Florida Memorial Hospital, Jacksonville, Florida, United States
πΊπΈUniversity of Florida Health Jacksonville, Jacksonville, Florida, United States
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT05347485
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈWashington University School Of Medicine, Saint Louis, Missouri, United States
πΊπΈCity of Hope, Duarte, California, United States
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT05346835
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈBanner MD Anderson Cancer Center, Gilbert, Arizona, United States
πΊπΈCancer Treatment Center of America Phoenix, Goodyear, Arizona, United States
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
- Conditions
- HIV-1
- Interventions
- Drug: D/C/F/TAF FDCDrug: TAF/FTC FDCDrug: INI Based Regimen
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT04442737
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈThe Office of Franco Felizarta, MD, Bakersfield, California, United States
πΊπΈAIDS Health Foundation-Westside HCC, Beverly Hills, California, United States
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- Conditions
- Crohn DiseaseColitis, Ulcerative
- Interventions
- Drug: Other Biologic Therapies
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1056
- Registration Number
- NCT04372108
- Locations
- πΊπΈ
NMCP, Portsmouth, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next